Verrica Pharmaceuticals (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Trading Halts

Verrica Pharmaceuticals Inc. (VRCA) Reports First Patient Enrollment in Phase 2 Trial of VP-102 for the Treatment of External Genital WartsJune 27, 2019 4:03 PM Verrica (VRCA) Phase 2 Clinical Study of VP-102 in Patients with Common Warts Achieved Primary EndpointJune 26, 2019 4:03 PM Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common WartsJune 26, 2019 4:02 PM Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common WartsJune 26, 2019 4:01 PM